 Adrenergic beta-Antagonists
"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
| Descriptor ID |
D000319
|
| MeSH Number(s) |
D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
|
| Concept/Terms |
Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
- Adrenergic beta Antagonists
- beta-Antagonists, Adrenergic
- beta-Adrenergic Receptor Blockaders
- Blockaders, beta-Adrenergic Receptor
- Receptor Blockaders, beta-Adrenergic
- beta Adrenergic Receptor Blockaders
- beta-Adrenergic Blockers
- Blockers, beta-Adrenergic
- beta Adrenergic Blockers
- beta-Blockers, Adrenergic
- Adrenergic beta-Blockers
- beta Blockers, Adrenergic
- Adrenergic beta-Receptor Blockaders
- Adrenergic beta Receptor Blockaders
- Blockaders, Adrenergic beta-Receptor
- beta-Receptor Blockaders, Adrenergic
- beta-Adrenergic Blocking Agents
- Agents, beta-Adrenergic Blocking
- Blocking Agents, beta-Adrenergic
- beta Adrenergic Blocking Agents
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 1996 | 7 | 3 | 10 | | 1997 | 5 | 0 | 5 | | 1998 | 4 | 0 | 4 | | 1999 | 4 | 2 | 6 | | 2000 | 6 | 0 | 6 | | 2001 | 8 | 7 | 15 | | 2002 | 3 | 0 | 3 | | 2003 | 6 | 2 | 8 | | 2004 | 5 | 2 | 7 | | 2005 | 3 | 6 | 9 | | 2006 | 3 | 5 | 8 | | 2007 | 8 | 3 | 11 | | 2008 | 9 | 2 | 11 | | 2009 | 4 | 1 | 5 | | 2010 | 8 | 3 | 11 | | 2011 | 5 | 4 | 9 | | 2012 | 7 | 1 | 8 | | 2013 | 8 | 3 | 11 | | 2014 | 5 | 2 | 7 | | 2015 | 3 | 3 | 6 | | 2016 | 4 | 2 | 6 | | 2017 | 3 | 4 | 7 | | 2018 | 3 | 6 | 9 | | 2019 | 3 | 6 | 9 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 3 | 4 | | 2024 | 2 | 4 | 6 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, Chahoud G, Mody KP, Saltzberg MT, Goldberg LR, Lindenfeld J, Sweitzer N, Butler J, Kittleson MM, Pina I, Paul S, Lewis EF, Wald J, Allen LA, Jessup M, Congdon M, Kiser R, Yancy C, Fonarow GC. Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF. Circ Heart Fail. 2025 May; 18(5):e012547.
-
Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, Berning AA, Minobe WA, Carroll IA, Jonas ER, Slavov D, Emani S, Abraham WT, Gollah AR, Ellis SL, Taylor MRG, Graw SL, Mestroni L, McKinsey TA, Buttrick PM, Kao DP, Bristow MR. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circ Heart Fail. 2025 Apr; 18(4):e012484.
-
Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC. ?-Blocker Use and Delayed Onset and Progression of Huntington Disease. JAMA Neurol. 2025 Jan 01; 82(1):85-92.
-
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 Dec 17; 13(24):e036998.
-
Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, Zheutlin AR, Shah KS, Greene SJ, Alhanti B, Blanco R, Fonarow GC. Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. Circ Heart Fail. 2025 Jan; 18(1):e012357.
-
Xu Y, Derington CG, Addo DK, He T, Jacobs JA, Mohanty AF, An J, Cushman WC, Ho PM, Bellows BK, Cohen JB, Bress AP. Trends in Initial Antihypertensive Medication Prescribing Among >2.8?Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. J Am Heart Assoc. 2024 Oct 15; 13(20):e036557.
-
Studinski MJ, Bowlus C, Pawelczyk JA, Delgado Spicuzza JM, Gosalia J, Mookerjee S, Muller MD, Fragin J, Proctor DN. Vascular limitations in blood pressure regulation with age in women: Insights from exercise and acute cardioselective ?-blockade. Exp Physiol. 2025 Jan; 110(1):93-105.
-
Zheng J, Sandhu AT, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, Greene SJ, Heidenreich PA, Lala A, Testani JM, Varshney AS, Wi RSK, Ambrosy AP. Inpatient Use of Guideline-Directed Medical Therapy During Heart?Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Fail. 2025 Jan; 13(1):43-54.
-
Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, Alhanti B, Van Spall HGC, Allen LA, Fonarow GC. Eligibility and Projected Benefits of Rapid?Initiation of Quadruple Therapy for Newly Diagnosed Heart?Failure. JACC Heart Fail. 2024 Aug; 12(8):1365-1377.
-
Lefkowitz RJ, Rockman HA, Shim PJ, Liu S, Ahn S, Pani B, Rajagopal S, Shenoy SK, Bouvier M, Benovic JL, Liggett SB, Ruffolo RR, Bristow MR, Packer M. How carvedilol does not activate ?2-adrenoceptors. Nat Commun. 2023 11 30; 14(1):7866.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|